Liposome Encapsulated Rifampicin and Isoniazid

Rifampicin and isoniazid (INH) in combination were formulated into liposomes for utilization as a delivery system for optimum therapeutic use in tuberculosis. A modified lipid layer hydration method was employed to prepare liposomes. The formulated liposomes were characterized for size distribution, drug loading and in vitro drug release studies. The liposomes prepared were in the size range 3.3 to 26.4 mm the mean diameter being 8.64mm. Entrapment efficiencies of 32.06% and 72.42% were obtained for INH and rifampicin in the liposomes respectively. In vitro release study on liposomes indicated 53.42% release for isoniazid and 35.99% for rifampicin. Stability study was carried out at different temperatures and it was found to be stable. In vivo antibacterial activity was determined by agar plate method in albino rats following the administration of liposomal formulation in comparison with drug alone and control. The liposomal drugs exhibited larger zone of inhibition as compared to the free drugs. Thus, it is evident from this study that liposomes could be promising delivery systems for rifampicin and INH with prolonged drug release profiles and better therapeutic effect.